Searchable abstracts of presentations at key conferences in endocrinology

ea0081p295 | Calcium and Bone | ECE2022

18Fluoro-choline PET/CT is a useful localization technique in patients with primary hyperparathyroidism

Pierotti Laura , Dinoi Elisa , Mazoni Laura , Apicella Matteo , Materazzi Gabriele , De Napoli Luigi , Bola Stefano , Faranda Alessio , Volterrani Duccio , Marcocci Claudio , Cetani Filomena

Primary hyperparathyroidism (PHPT) is a common endocrine disease mainly caused by a single parathyroid adenoma. Although the localization of the parathyroid adenoma is not a surgical criterion for parathyroidectomy (PTX), this is known to increase the cure rate and reduce the complication rate. Neck ultrasound and MIBI-scintigraphy are the first-line techniques to detect hyperfunctioning parathyroid tissue, however, they have some limitations including the operator-dependent s...

ea0084ps2-10-89 | Nodules & Cancer | ETA2022

Follicular thyroid neoplasm with papillary-like nuclear features (NIFT-P) showed peculiar ultrasonographic features compared to follicular variant of papillary thyroid carcinoma (FV-PTC), follicular carcinoma (FTC) and follicular adenoma (FA)

De Napoli Luigi , Matrone Antonio , Gambale Carla , Pieroni Erica , Boni Giulia , Aghababyan Aleksandr , Enrico Ambrosini Carlo , Torregrossa Liborio , Basolo Fulvio , Materazzi Gabriele , Elisei Rossella

Background: Up to 2016, NIFT-P was considered a non-invasive encapsulated follicular variant of papillary thyroid carcinoma (FV-PTC) and was reclassified and downgraded to a pre-malignant lesion. However, if these nodules have peculiar ultrasonographic features able to pre-operatively suggest their histology is still a matter of discussion. We evaluated a large series of NIFT-P, FV-PTC, FTC, and FA to characterize their ultrasonographic features.Methods:...

ea0092ps3-29-06 | Treatment 2 | ETA2023

Dabrafenib and trametinib treatment in patients with braf-mutated advanced thyroid cancer

Contartese Lea , Prete Alessandro , Gambale Carla , Torregrossa Liborio , Papini Piermarco , De Napoli Luigi , Minaldi Elisa , Materazzi Gabriele , Molinaro Eleonora , Elisei Rossella , Matrone Antonio

Introduction: The combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) was approved by the Food and Drug Administration in USA as first line treatment for BRAF-positive anaplastic thyroid cancer. Moreover, it was also available as second line treatment in BRAF-positive advanced thyroid cancers, previously treated with other systemic treatments.Purpose: We evaluated the efficacy and safety of the combination therapy with dabrafenib an...